SBHMY (Sino Biopharmaceutical) Margin of Safety % (DCF FCF Based): N/A (As of Jul. 03, 2026)


SBHMY Sino Biopharmaceutical Ltd SBHMY
88 GF Score
Price $12.68
GF Value $12.81
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Sino Biopharmaceutical Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Sino Biopharmaceutical's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

SBHMY vs VRTX, REGN, ALNY: Margin of Safety % (DCF FCF Based) Comparison

For the Biotechnology subindustry, Sino Biopharmaceutical's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sino Biopharmaceutical Margin of Safety % (DCF FCF Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sino Biopharmaceutical's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Sino Biopharmaceutical's Margin of Safety % (DCF FCF Based) falls into.


SBHMY
88GF Score
Sino Biopharmaceutical Ltd SBHMY
Margin of Safety % (DCF FCF Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Sino Biopharmaceutical (SBHMY) Overvalued in 2026?

Based on GuruFocus' analysis, Sino Biopharmaceutical stock appears to be undervalued. The current stock price of $12.68 is trading 1% below its estimated GF Value™ of $12.81. GuruFocus considers Sino Biopharmaceutical to be Fairly Valued.

Key valuation signals for SBHMY:

  • Margin of Safety % (DCF FCF Based): N/A
  • GF Value™: $12.81 vs. price of $12.68 (1% below fair value)
  • GF Score™: 88/100 with 4 warning signs

No single metric tells the full story. See the SBHMY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sino Biopharmaceutical Business Description

Address 1 Harbour Road, Unit 09, 41st Floor, Office Tower, Room 4109, Convention Plaza, Wanchai, Hong Kong, HKG
Sino Biopharmaceutical Ltd is an investment holding company. The company and its subsidiaries are principally engaged in the research and development, production and sale of a series of pharmaceutical products. Its business covering the entire industrial chain of R&D, production and commercialization of drugs, biological products and high-end generic drugs. The company's therapeutic areas include: oncology, liver disease, respiratory, and surgery/pain relief. The company's revenue was generated from the sale of pharmaceutical products in the Chinese mainland.
88GF Score

Get the complete analysis for SBHMY

Margin of Safety % (DCF FCF Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.68
Price
$12.81
GF Value